Biosimilars could help healthcare costs

Sam Taylor, the president of the North Carolina Biosciences Organization and James C. Greenwood, President and CEO, Biotechnology Industry Organization recently wrote an opinion piece about how the approval of a pathway for biosimlars, which could help tremendously when it comes to healthcare and reducing the costs of both medicine and care.

The letter states:
Done correctly, an approval process for biosimilars will protect patient safety, expand competition to reduce costs for consumers, and provide fair incentives for continued biomedical innovation.

As well as:
In considering biosimilars legislation, Congress must maintain incentives for continued investment in order to realize the full potential of this sector to provide new therapies and even cures to patients.

Read the full article here.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |